TELO
Telomir Pharmaceuticals, Inc. (NASDAQ)
Healthcare — Biotechnology
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Price History
Fundamentals
| Market Cap | $89.41M |
| P/E Ratio (TTM) | - |
| Forward P/E | -4.64 |
| EPS (TTM) | $-0.29 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -384.26% |
| Debt/Equity | 11.04 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 54.0 |
| Beta | -0.23 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $3.10 |
| 52-Week Low | $1.05 |
| 50-Day Avg | $1.30 |
| 200-Day Avg | $1.35 |
| Avg Volume | 154.4K |
| Volume | 1.9K |
Performance Analysis
NEUTRALTELO presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:34 UTC
Back to Screener Export Report